Homepage0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Vorige slotkoers
$Â 0,41
Dag-range
$Â 0,41 - $Â 0,42
Jaar-range
$Â 0,30 - $Â 0,62
Beurswaarde
3,94Â mld. HKD
Gem. volume
887,22K
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
Marktnieuws
MarketScreener
9 uur geleden
Wall Street profiteert van sterke bedrijfscijfers en meevallende inflatie
1,83%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (HKD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,32Â mld. | 2,20% |
Bedrijfskosten | 323,51Â mln. | -4,23% |
Netto inkomsten | 500,50K | -97,29% |
Netto winstmarge | 0,04 | -97,20% |
Winst per aandeel | — | — |
EBITDA | 117,12Â mln. | 36,03% |
Effectief belastingtarief | 79,96% | — |
Balans
Totale activa
Totale passiva
| (HKD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 562,09Â mln. | 11,10% |
Totale activa | 10,89Â mld. | -1,45% |
Totale passiva | 6,87Â mld. | -0,11% |
Totaal aandelenvermogen | 4,01 mld. | — |
Uitstaande aandelen | 9,61 mld. | — |
Koers-boekwaardeverhouding | 0,98 | — |
Rendement op activa | 1,75% | — |
Rendement op kapitaal | 1,91% | — |
Kasstroom
Nettomutatie in liquide middelen
| (HKD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 500,50K | -97,29% |
Operationele kasstroom | 72,70Â mln. | 80,63% |
Kasstroom uit beleggingen | -47,88Â mln. | -484,81% |
Kasstroom uit financiering | -77,72Â mln. | 41,39% |
Nettomutatie in liquide middelen | -57,56Â mln. | 42,02% |
Vrije kasstroom | 35,56Â mln. | 91,21% |
Over
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
1.968
